Trust Signals
This page was written by the FormBlends Medical Team, referencing primary trial data (Jastreboff et al., NEJM 2023) and established pharmacokinetic principles. Every dose figure is traced to a real source. Where evidence is limited or absent, the page says so explicitly. No dose on this page constitutes medical advice or a prescription.
Key Takeaways
- The unit number on a syringe is volume, not mass. At 5 mg/mL, a 2 mg dose is 40 units. At 2 mg/mL, the same 2 mg dose is 100 units. The concentration of your vial determines everything.
- The Eli Lilly Phase 2 trial (Jastreboff et al., NEJM 2023) tested multiple weekly dose levels up to 12 mg, starting all active arms at 2 mg weekly with stepwise escalation roughly every 4 weeks. See the published paper for the complete dose-arm structure.
- At 24 weeks, the highest dose group achieved a mean body weight reduction of approximately 17.5%, the largest signal reported in the trial.
- Retatrutide is not FDA approved as of May 2026. Research-grade vials have no regulatory purity guarantee, making concentration verification against a certificate of analysis (COA) critical before any dose calculation.
- GI adverse events in the trial were dose-dependent. Higher doses produced higher rates of nausea and vomiting, particularly during titration weeks.
Direct Answer: How Many Units of Retatrutide Should I Take?
There is no single unit number. The correct answer depends on your vial's concentration in mg/mL. Divide your intended milligram dose by the concentration, then multiply by 100 to get units on a U-100 insulin syringe. A 2 mg dose from a 5 mg/mL vial equals 40 units. Verify your vial's COA before drawing any dose.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Unit Math: The Conversion Formula Explained
- Evidence Ledger: What the Trial Data Actually Shows
- Mechanism and Receptor Targets with Specific Numbers
- What Titration Schedule Did the Trial Use?
- What Most Pages Get Wrong About Retatrutide Units
- Stability and Formulation: The Gotcha Nobody Mentions
- Honest Head-to-Head: Retatrutide vs. Semaglutide vs. Tirzepatide
- Label and COA Literacy: How to Read Your Vial
- FAQ
- Sources
- Disclaimers
Unit Math: The Conversion Formula Explained
Insulin syringes are calibrated for U-100 insulin, meaning 100 units equals 1 mL. That unit scale has nothing inherently to do with retatrutide. When researchers draw peptides using insulin syringes, they are measuring volume, and the milligram dose delivered depends entirely on how concentrated the solution is.
The formula:
Units = (Desired dose in mg / Concentration in mg/mL) x 100
| Desired Dose (mg) | Vial Concentration (mg/mL) | Units to Draw (U-100 syringe) | Volume (mL) |
|---|---|---|---|
| 1 mg | 2 mg/mL | 50 units | 0.5 mL |
| 1 mg | 5 mg/mL | 20 units | 0.2 mL |
| 2 mg | 2 mg/mL | 100 units | 1.0 mL |
| 2 mg | 5 mg/mL | 40 units | 0.4 mL |
| 4 mg | 5 mg/mL | 80 units | 0.8 mL |
| 8 mg | 5 mg/mL | 160 units (requires 2 syringes or a 2 mL draw) | 1.6 mL |
| 12 mg | 5 mg/mL | 240 units | 2.4 mL |
Reconstitution math: Most research vials arrive as lyophilized powder labeled in total milligrams (for example, 10 mg per vial). Adding 2 mL of bacteriostatic water yields 5 mg/mL. Adding 5 mL yields 2 mg/mL. The amount of water you add determines every dose you subsequently draw. Write the concentration on the vial label immediately after reconstitution.
Evidence Ledger: What the Trial Data Actually Shows
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Retatrutide produces meaningful weight loss in adults with obesity | Phase 2 human RCT (Jastreboff et al., NEJM 2023, 24 weeks; see paper for enrollment details) | Positive (dose-dependent) | Moderate (Phase 2 only, no Phase 3 published) |
| Highest tested dose produced approximately 17.5% mean body weight loss at 24 weeks | Phase 2 RCT primary endpoint | Positive | Moderate |
| GI side effects are dose-dependent | Phase 2 RCT adverse event reporting | Dose-response confirmed | Moderate |
| GIP receptor agonism contributes to weight loss above GLP-1 alone | Mechanistic/preclinical and Phase 2 data | Positive (additive/synergistic hypothesis) | Low (mechanism not isolated in humans) |
| Glucagon receptor agonism improves lipid metabolism | Preclinical animal and early human data | Positive directionally | Low |
| Retatrutide is safe for long-term human use | No Phase 3 data published; no approved label | Unknown | Very Low |
| Research-grade vials match labeled concentration | No peer-reviewed verification; vendor COA only | Variable | Very Low |
Mechanism and Receptor Targets with Specific Numbers
Retatrutide is a single acylated peptide that acts as a triagonist at three G-protein-coupled receptors: GLP-1R (glucagon-like peptide-1 receptor), GIPR (glucose-dependent insulinotropic polypeptide receptor), and GCGR (glucagon receptor). This distinguishes it from tirzepatide (dual GLP-1R/GIPR) and semaglutide (GLP-1R only).
According to data reported in the Jastreboff 2023 NEJM paper and Lilly's published pharmacology work:
- GLP-1R activation reduces appetite, slows gastric emptying, and enhances glucose-dependent insulin secretion.
- GIPR activation contributes to satiety signaling and may reduce the nausea burden of pure GLP-1R agonism at equivalent weight-loss efficacy, based on preclinical and early human data.
- GCGR activation increases energy expenditure and hepatic fat oxidation, providing a mechanistic rationale for the lipid and hepatic outcomes observed in early studies.
What the mechanism does NOT prove: Receptor binding studies and animal data cannot directly predict the magnitude or durability of weight loss in diverse human populations. The additive or synergistic contribution of each receptor arm has not been cleanly isolated in a human controlled design.
Retatrutide has a half-life suited for once-weekly subcutaneous dosing, consistent with the Phase 2 trial design. This is achieved through fatty acid acylation that extends albumin binding and slows renal clearance, an approach similar to that used in semaglutide. Specific binding affinity constants for research-grade (non-pharmaceutical) retatrutide are not publicly verified and should not be assumed to match the pharmaceutical compound.
What Titration Schedule Did the Trial Use?
In the Jastreboff 2023 Phase 2 trial, all active arms started at 2 mg weekly. Doses were escalated in steps approximately every 4 weeks toward the assigned target dose. The step-up design was intended to reduce GI adverse events during the adaptation period. For the specific dose levels tested in each arm, consult the published paper directly (doi:10.1056/NEJMoa2301972).
A representative research titration framework derived from the trial's general structure (not a clinical recommendation):
| Week | Dose (mg, weekly) | Units at 5 mg/mL |
|---|---|---|
| 1 to 4 | 2 mg | 40 units |
| 5 to 8 | 4 mg | 80 units |
| 9 to 12 | 8 mg (if targeting 8 or 12 mg) | 160 units |
| 13 onward | 12 mg (maintenance, highest dose arm) | 240 units |
What Most Pages Get Wrong About Retatrutide Units
Most online guides state a unit number without ever naming the vial concentration they assumed. This creates serious dosing errors when users have a different concentration. A page that says "take 40 units" is implicitly assuming 5 mg/mL. If your vial is 2 mg/mL and you draw 40 units, you receive 0.8 mg, less than half the intended 2 mg dose. If your vial is 10 mg/mL and you draw 40 units, you receive 4 mg, double the intended dose.
The second common error is treating research-grade retatrutide concentration claims as reliable without a COA. Third-party tested research peptides frequently deviate from labeled concentration in independent assays. Several independent testing projects on research peptides (not specific to retatrutide, but applicable to the category) have documented meaningful purity and concentration variance between vendors. Until a retatrutide COA from a credentialed independent lab (HPLC with mass spectrometry) is in hand, the labeled concentration is an approximation.
The third error is copying doses from forum posts without knowing whether those posts assumed weekly or daily dosing. Retatrutide in the Phase 2 trial was dosed weekly. Daily subcutaneous dosing at weekly milligram amounts would be a dangerous overdose.
Stability and Formulation: The Gotcha Nobody Mentions
Retatrutide is a peptide. Peptides are vulnerable to degradation through several pathways that affect potency without any visible change to the solution.
Why bacteriostatic water matters: Bacteriostatic water contains 0.9% benzyl alcohol as a preservative. This is the correct reconstitution solvent for multi-draw research vials because it suppresses bacterial growth over weeks of refrigerated storage. Plain sterile water (for injection) lacks this preservative. A vial reconstituted with plain sterile water should ideally be used within a shorter window, as contamination risk increases with each needle entry. The chemistry: benzyl alcohol disrupts bacterial cell membranes at bacteriostatic concentrations without meaningfully denaturing peptide bonds at the concentrations used.
Freeze-thaw degradation: Repeated freeze-thaw cycles promote peptide aggregation. Aggregated peptide may still appear clear but has reduced receptor binding activity. Once reconstituted, do not freeze the vial. Store at 2 to 8 degrees Celsius (standard refrigerator).
Light and agitation: UV exposure and vigorous shaking can accelerate oxidation of susceptible amino acid residues (particularly methionine if present) and disulfide scrambling. Swirl gently, do not shake. Store in original dark vial or wrapped in foil.
Lyophilized powder stability: Unreconstituted lyophilized powder is substantially more stable than solution. Many vendors state extended shelf life for lyophilized product stored at freezer temperatures, but formal stability data for research-grade retatrutide specifically are not publicly available. Reconstitute only what you will use within 4 weeks.
What degraded product looks like: Cloudiness, particulate matter, yellow or brown discoloration, or gel-like viscosity after reconstitution are all discard criteria. A clear, colorless solution does not guarantee potency, but visible changes are absolute contraindications to use.
Honest Head-to-Head: Retatrutide vs. Semaglutide vs. Tirzepatide
| Attribute | Retatrutide | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|---|
| Receptor targets | GLP-1R, GIPR, GCGR (triple) | GLP-1R (single) | GLP-1R, GIPR (dual) |
| Regulatory status | Investigational (Phase 3 ongoing) | FDA approved (2.4 mg weekly) | FDA approved (up to 15 mg weekly) |
| Best published weight loss (Phase 2/3) | Approximately 17.5% at 24 weeks (highest dose arm, Phase 2; Jastreboff et al., NEJM 2023) | Approximately 14.9% at 68 weeks (STEP 1, Phase 3) | Approximately 20.9% at 72 weeks (SURMOUNT-1, Phase 3) |
| Purity guarantee | None (research-grade only) | Full pharmaceutical GMP | Full pharmaceutical GMP |
| Dosing accuracy | Dependent on reconstitution math; COA required | Pre-filled auto-injector pen; fixed dose | Pre-filled auto-injector pen; fixed dose |
| Long-term safety data | Not available | Multi-year cardiovascular outcome trial data (SELECT) | Growing Phase 3 data; shorter post-market history |
| Where retatrutide loses | No approval, no purity guarantee, no long-term data, no device convenience | Lower peak weight loss in available data | Slightly lower peak weight loss than retatrutide Phase 2; no glucagon arm |
Honest conclusion: Retatrutide's Phase 2 efficacy signal is compelling, but comparing a 24-week Phase 2 result against 68-to-72-week Phase 3 results is methodologically imperfect. Trial durations, populations, and endpoints differ. A direct head-to-head trial has not been completed. Approved medications carry a safety and quality assurance advantage that a research compound cannot replicate.
Label and COA Literacy: How to Read Your Vial
When evaluating a research-grade retatrutide vial or COA, check for the following:
| What to Check | What It Means | Red Flag |
|---|---|---|
| Purity percentage (HPLC) | Proportion of the total mass that is the target peptide | Below 98% for research use; no method specified |
| Molecular weight confirmation (MS) | Mass spectrometry confirms the peptide identity | COA lacks MS data; purity by UV only |
| Labeled mg per vial | Total peptide mass before reconstitution | No batch number; no test date |
| Endotoxin testing | Bacterial endotoxin levels (LAL assay); relevant for injection safety | Absent from COA entirely |
| Reconstitution instructions | Volume of bacteriostatic water to add (determines final concentration) | No instructions; forces you to guess the volume |
Calculate your dose only after confirming the mg/vial figure on the COA and deciding your reconstitution volume. Write the resulting mg/mL on the vial in permanent marker, along with the reconstitution date.
FAQ
How many units of retatrutide should I take?
The answer depends entirely on your vial concentration. A common research vial holds 10 mg in 2 mL (5 mg/mL). At that concentration, a 2 mg dose equals 40 units on an insulin syringe. Never use a unit number without first confirming your vial's mg/mL concentration.
What concentration is retatrutide usually sold in?
Research-grade retatrutide is most commonly supplied as lyophilized powder that must be reconstituted. Concentrations after reconstitution vary widely by vendor, typically ranging from 2 mg/mL to 5 mg/mL depending on how much bacteriostatic water is added.
How do I convert milligrams to insulin syringe units?
Formula: units = (dose in mg / concentration in mg per mL) x 100. Example: 2 mg dose at 5 mg/mL = (2/5) x 100 = 40 units. At 2 mg/mL the same 2 mg dose = 100 units (a full 1 mL syringe).
What doses were used in the Phase 2 retatrutide trial?
The Eli Lilly Phase 2 trial (Jastreboff et al., NEJM 2023) tested multiple weekly dose levels escalating up to 12 mg. The highest dose group achieved mean body weight reduction of approximately 17.5% at 24 weeks. Refer to the published paper for the full dose-arm breakdown.
What is the typical titration schedule for retatrutide?
The Phase 2 protocol started participants at 2 mg weekly and escalated every 4 weeks toward the target dose. Rapid escalation increases GI side effects. No approved label exists; any titration outside a supervised protocol is off-label research use.
Can I use the same unit number every time regardless of vial?
No. Units are volume, not mass. If you switch vials or vendors and the concentration changes, the same unit number delivers a completely different milligram dose. Always recalculate when opening a new vial.
What syringe should I use to draw retatrutide?
Standard U-100 insulin syringes (1 mL, 100 units marked) are the conventional choice for subcutaneous peptide administration in research settings. Confirm the syringe is U-100 before applying the unit conversion formula.
Is retatrutide FDA approved?
No. As of May 2026, retatrutide is not FDA approved. It is an investigational compound being developed by Eli Lilly. Research-grade vials sold by peptide vendors are not pharmaceutical-grade and carry no regulatory oversight for purity or dosing accuracy.
How does retatrutide compare to semaglutide for weight loss?
In its Phase 2 trial, retatrutide's highest dose group achieved roughly 17.5% body weight loss at 24 weeks. Semaglutide 2.4 mg (Wegovy) achieved approximately 14.9% at 68 weeks in the STEP 1 trial. Direct head-to-head trials have not been completed, and the trial durations differ substantially.
What are the main side effects and do they depend on dose?
Yes, GI side effects (nausea, vomiting, diarrhea) are dose-dependent and were most common during titration in the Phase 2 trial. Higher dose groups had higher discontinuation rates due to adverse events compared to placebo.
How should a reconstituted retatrutide vial be stored?
After reconstitution with bacteriostatic water, store at 2 to 8 degrees Celsius (standard refrigerator temperature). Avoid freeze-thaw cycles. Most vendors recommend use within 4 weeks of reconstitution, though formal stability data for research-grade product are not publicly available.
What does a degraded or contaminated retatrutide vial look like?
Visual flags include cloudiness or particulate matter after reconstitution (the solution should be clear and colorless), color change to yellow or brown, and any visible crystallization. If any of these appear, discard the vial.
Sources
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216.
- Lilly I. Retatrutide (LY3437943) Investigational Drug Information. Eli Lilly and Company investor and clinical trial disclosures, 2023 to 2024. ClinicalTrials.gov NCT04881760.
- FDA. Wegovy (semaglutide) Prescribing Information. U.S. Food and Drug Administration. Revised 2023.
- FDA. Zepbound (tirzepatide) Prescribing Information. U.S. Food and Drug Administration. 2023.
- Drucker DJ. The biology of incretin hormones. Cell Metabolism. 2006;3(3):153-165.
- Lau J, Bloch P, Schaffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015;58(18):7370-7380. (Cited for fatty acid acylation half-life extension principles applicable to the compound class.)